Feb 26 |
Mesoblast Financial Results and Corporate Update Webcast
|
Feb 15 |
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
|
Jan 31 |
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
|
Jan 19 |
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
|
Jan 18 |
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
|
Jan 9 |
Mesoblast (ASX:MSB) investors are sitting on a loss of 88% if they invested three years ago
|
Jan 5 |
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
Dec 21 |
5 Stocks to Ride the Santa Claus Rally
|
Nov 26 |
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
|
Nov 23 |
Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
|